New portal online about clinical trials worldwide.

A new portal (www.ifpma.org/clinicaltrials), established by the International Federation of Pharmaceutical Manufacturers and Associations, links available online information about clinical trials worldwide.

Comments

Post a Comment

Popular posts from this blog

Once-Daily 'Male Pill' Shows Promise in Early Study

Image
CHICAGO, Illinois — An investigational oral synthetic androgen shows promise as a possible male contraceptive pill in a new month-long study. Dose-finding and safety results of the trial in 82 healthy men were presented March 18 here ENDO 2018: The Endocrine Society Annual Meeting by Arthi Thirumalai, MBBS, acting assistant professor, University of Washington, Seattle. "It only needs to be dosed once a day, and we didn't see any significant side effects, but it needs to be tested much longer. This is a very early phase," Study coauthor Stephanie Page, MD, PhD, professor of medicine at the university, told Medscape Medical News. The agent, dimethandrolone undecanoate (DMAU), is a prodrug that is converted to dimethandrolone (DMA), which binds to both androgen and progesterone receptors. The long-chain fatty acid component undecanoate slows the drug's clearance, enabling the once-daily dosing. During a press briefing, Page showed data from a multinational surv
Read more

Inflamation and Alzheimer disease

Image
A new study shows that microglia, which are the immune cells of the central nervous system, can "remember" inflammation. This "memory" influences how the cells react to new stimuli and deal with toxic plaque in the brain, a marker of Alzheimer's disease. The brain's immune cells remember previous inflammation. Microglia, sometimes referred to as "scavenger" cells, "are the primary immune cells of the central nervous system." As the key player in the brain's immunity, microglia are dispatched to the site of infection or injury, where they fight toxic agents or pathogens and get rid of useless cells. However, these cells are also known to play a negative role in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, ischemic stroke, and traumatic brain injuries. For instance, a recent study showed that when microglia are overactive, they devour toxic plaques along with synapses, which presumably lead
Read more

spondyloarthritis (SpA), Diclofenac and Myocardial Infarction

Image
NEW YORK (Reuters Health) - Risk of myocardial infarction (MI) is increased in patients with spondyloarthritis (SpA) who use the nonsteroidal anti-inflammatory drug (NSAID) diclofenac but not in those who take naproxen, researchers say. Dr. Maureen Dubreuil of Boston University School of Medicine and colleagues analyzed 20 years of medical records from the UK's Health Improvement Network for adults ages 18 to 89 with incident ankylosing spondylitis (AS) or psoriatic arthritis (PsA), two forms of SpA. Controls had incident osteoarthritis (OA). Within each cohort, the team then matched each MI case to four controls without MI. NSAID use was categorized as (a) current (prescription within 180 days prior to index date); (b) recent (181-365 days) or (c) remote (>365 days). The daily dosage of diclofenac was 100 mg or more in 92% of individuals with OA, 95% of those with AS, and 92% of those with PsA. The most common daily dosage of naproxen was 1,000 mg (55%); the dose was 1
Read more